Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

First details of lurasidone's Phase III efficacy in bipolar depression

01:35 EST 6 Nov 2013 | SCRIP

In June, the multi-modal molecule became the first atypical antipsychotic to be approved for use in the US for adults with major depressive episodes associated with bipolar I disorder, both as a monotherapy and an adjunctive therapy to the mood...

Original Article: First details of lurasidone's Phase III efficacy in bipolar depression

NEXT ARTICLE

More From BioPortfolio on "First details of lurasidone's Phase III efficacy in bipolar depression"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Story